Navigation Links
Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis

SAN DIEGO, Oct. 4 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its APTIMA® Trichomonas vaginalis assay on the fully automated TIGRIS® system.

"Trichomonas is the most common curable sexually transmitted disease in young women, and it can lead to serious health consequences if left untreated," said Carl Hull, Gen-Probe's president and chief executive officer.  "We believe our Trichomonas vaginalis assay will contribute significantly to women's health and provide a convenient tool for physicians and laboratories.  Our assay employs the same technology as our market-leading APTIMA tests for Chlamydia and gonorrhea, can be used with the same female samples, and runs on our unique, fully automated TIGRIS system.

"In addition, this regulatory application represents the third of five that we plan to complete in the United States this year.  Taken together, we expect these new products to start an important new sales growth cycle for the Company."

Trichomonas is a sexually transmitted parasite that causes vaginitis, urethritis and cervicitis in women.  If left untreated, complications can include premature labor, low-birth-weight offspring, and premature membrane rupture in pregnancy.  Studies have shown that Trichomonas infection also makes women more susceptible to infection with HIV-1, the virus that causes AIDS, and contributes to increased persistence of the Human Papillomavirus (HPV), which causes cervical cancer.  The US Centers for Disease Control estimate that 7.4 million American men and women are infected with Trichomonas annually, making it more prevalent than Chlamydia and gonorrhea combined.

Screening for Trichomonas is limited today due in part to the shortfalls of current testing techniques.  Most testing currently is done via culture methods, which are slow and less sensitive than molecular tests, or "wet mount," which requires the microscopic examination of a sample shortly after it is collected.

Gen-Probe's APTIMA Trichomonas vaginalis assay has been CE marked for sale in the European Union, but has not been cleared for marketing in the United States.

About Gen-ProbeGen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 27 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,300 people. For more information, go to

Caution Regarding Forward-Looking StatementsAny statements in this press release about Gen-Probe's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would.  For example, statements concerning new products, potential regulatory approvals, customer adoption, and results of future R&D studies are all forward-looking statements.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied.  These risks, uncertainties and assumptions include, but are not limited to: (i) the risk that new products, such as our APTIMA Trichomonas vaginalis assay, will not be cleared for marketing in the timeframe we expect, if at all, (ii) the possibility that the market for the sale of our new products, such as our APTIMA Trichomonas vaginalis assay, may not develop as expected, and (iii) the risk that we may not be able to compete effectively.  The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements.  For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.Contact:Michael WattsVice president, investor relations andcorporate communications858-410-8673

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
2. Neogen Acquires Gen-Probes BioKits Food Safety Business
3. Gen-Probe to Webcast Two Upcoming Investor Presentations
4. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
5. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
6. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
7. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
8. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
9. Peptimmune Files Citizen Petition Regarding Generic Copaxone and Demonstrates Significant Enabling Technology for Biological Characterization of Copaxone
10. Volcano Corporation Files Counterclaim Asserting St. Jude Infringes Three Volcano Patents; Answers St. Judes Patent Infringement Claims
11. China-Biotics Files New Patent Applications
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):